Premium
Mycophenolate use in dermatology: A clinical audit
Author(s) -
Li Jane,
Chong Alvin H,
Green Jack,
Kelly Robert,
Baker Christopher
Publication year - 2013
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12042
Subject(s) - medicine , tolerability , atopic dermatitis , dermatology , adverse effect , pyoderma gangrenosum , topical steroid , retrospective cohort study , surgery , disease
Mycophenolate use in dermatology is growing due to its reputation as a steroid‐sparing agent with a favourable side‐effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted a retrospective clinical audit in 33 dermatology patients who had received mycophenolate at our institution between A pril 2010 and J anuary 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent of patients showed some benefit from mycophenolate treatment, with 12 per cent failing to respond. Side‐effects were experienced by 45 per cent of patients, two of whom had serious side‐effects. Female sex appears to be a risk factor for adverse effects. We conclude that although mycophenolate is a promising agent across a variety of dermatological conditions, further randomised controlled trials are required.